Medical Intl Tech (MDLH) fair value: what the stock is really worth
As of Sep 25, 2026: fair value of Medical Intl Tech $0.00, price $0.00, upside +0.0%, quality 54 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Medical Intl Tech for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
Medical International Technology, Inc. produces, markets, and sells needle-free jet injector products for use in humans and animals.
Show more
Medical International Technology, Inc. produces, markets, and sells needle-free jet injector products for use in humans and animals. It offers Med-Jet model needle-free injection systems for medical, cosmetic dermatology, and mesotherapy applications, as well as for single and mass vaccination in humans; Agro-Jet and Avian-Jet needle-free injection systems for small farm animal, pets clinic use, and livestock vaccination; Avian-Jet needle-free injectors for poultry vaccination; and MINI-JET for day old chick vaccination. The company sells its products to doctors, dentists, nurses, veterinarians, farmers, and home users in approximately 30 countries, including the United States. Medical International Technology, Inc. is based in Montreal, Canada.
Stock analysis
Medical Intl Tech (MDLH) currently trades at $0.0001, while our model-based Fair Value estimate is $0.0001, so the stock looks roughly fairly valued today (gap 0.0%).
Show more
Valuation
Bull case: the Growth DCF group reads highest at a median of $0.0001 per share, and 0 of the 9 models we run sit above the $0.0001 price.
Bear case: the DCF Models group reads lowest at $0.0001, and 9 of the 9 models stay below the price. Evidence for this calculation is low.
Quality & growth
The Quality Score stands at 54/100 (solid quality), in the Healthcare sector.
Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Medical Intl Tech reported revenue of $545K in FY2015 versus $996K in FY2012, a compound −18.2%/yr. Reported net income was −$61.1K in FY2015.
Key figures
Market cap $8.4K · P/S ratio 0.02 · Net margin −11.2% · Return on equity −285% · Return on assets (EBIT) −1.6% · Operating margin −333% · Revenue (TTM) $398K · Revenue growth (YoY) −63.9%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 50 out of 100 (low confidence).
What moves the price
The share trades at its 52-week high and at its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −38% fair-value upside, at 0%, MDLH screens cheaper than that median.
Fair Value models
Bear $0.0001Fair Value $0.0001Bull $0.0001
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.21/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
+28.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−18.2%
’12
’13
’14
’15
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
2.7% (2012) → −7.8% (2015)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: no share-count history
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Instruments & Supplies · 189 stocks
Beats the industry median on 2/7 measures
Overall it trails its industry peers.
Valuation
Quality Score54 · Below median
Fair Value upside+0.0% · Above median
Profitability
Return on assets−35.5% · Bottom 25%
Net margin (TTM)−103.0% · Bottom 25%
Growth and dividend
Revenue growth−63.9% · Bottom 25%
Balance sheet
Debt / equity0.14× · Above median
Valuation Multiplesvs Medical Instruments & Supplies median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Medical Intl Tech (MDLH) overvalued or undervalued?
As of Sep 27, 2026, our model estimates a fair value of $0.0001 versus the last price from Sep 25, 2026 of $0.0001, about +0% upside (fairly valued).
What is the fair value of MDLH?
Our model-based fair value for Medical Intl Tech is $0.0001 (as of Sep 27, 2026), built from audited fundamentals. Last price (from Sep 25, 2026): $0.0001.
What is the quality score of MDLH?
Medical Intl Tech has a Quality Score of 54/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Medical Intl Tech (MDLH)?
Our model-based price target is the fair value of $0.0001 (as of Sep 27, 2026) from 9 valuation models. It is a calculation from audited fundamentals, not an analyst target.
What is the Medical Intl Tech stock forecast for 2026?
Our models put fair value at $0.0001, about +0% upside versus the last price from Sep 25, 2026 of $0.0001 (fairly valued). The calculation is refreshed regularly with new filings.
What is the revenue of Medical Intl Tech (MDLH)?
Medical Intl Tech reported trailing-twelve-month revenue of about $398K (latest available figure, as of Sep 27, 2026).
What is the intrinsic value of Medical Intl Tech (MDLH)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Medical Intl Tech it is $0.0001 per share (as of Sep 27, 2026), against a price of $0.0001. It is the blended result of 9 valuation models (cash flow, earnings, asset, dividend).
Is Medical Intl Tech stock overvalued or undervalued in 2026?
As of Sep 27, 2026, MDLH trades below its calculated fair value: price $0.0001, fair value $0.0001, a gap of about +0% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of MDLH?
No. The price is what the market pays today ($0.0001); the fair value is what the company's own numbers justify ($0.0001). For Medical Intl Tech the two are $0.0000 per share apart. That gap is exactly why we show both numbers side by side.
How much is Medical Intl Tech worth?
The market values Medical Intl Tech at about $8.4K (market capitalisation, as of Sep 27, 2026). Per share that is $0.0001; our models calculate a fair value of $0.0001 per share.
How solid is the balance sheet of Medical Intl Tech (MDLH)?
Balance-sheet figures for Medical Intl Tech (as of Sep 27, 2026): return on equity −285.2%, debt of 0.14 per unit of equity. They feed the Quality Score of 54/100, which measures business quality independently of the share price.
How far is MDLH from its 52-week high?
Medical Intl Tech trades at $0.0001, at its 52-week high of $0.0001 and at the low of $0.0001 (as of Sep 25, 2026). Distance from the high says nothing about value: that is what the fair value of $0.0001 is for.
Which stocks are comparable to Medical Intl Tech?
From the same area (Healthcare) we also value Intuitive Surgical, Inc, EssilorLuxottica Société anonyme, Becton, Dickinson and Company, Medline Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Medical Intl Tech stock attractive at the current price?
The data as of Sep 27, 2026: price $0.0001, calculated fair value $0.0001 (+0%), Quality Score 54/100, from 9 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of MDLH calculated?
We run Medical Intl Tech through 9 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.0001, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Medical Intl Tech itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Medical Intl Tech (MDLH)?
The latest price we hold is from Sep 25, 2026 and stands at $0.0001. Our model-based fair value is $0.0001, about +0% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Medical Intl Tech right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Key figures of Medical Intl Tech
How large is the market capitalisation of Medical Intl Tech (MDLH)?
The market capitalisation of Medical Intl Tech is $8.4K. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Medical Intl Tech (MDLH)?
The price-to-sales ratio of Medical Intl Tech is 0.02 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the net margin of Medical Intl Tech (MDLH)?
The net margin of Medical Intl Tech is −11.2% (fiscal year 2015). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Medical Intl Tech (MDLH)?
The return on equity (ROE) of Medical Intl Tech is −285% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Medical Intl Tech (MDLH)?
On an EBIT basis the return on assets of Medical Intl Tech is −1.6% (avg 4y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Medical Intl Tech (MDLH)?
The operating margin of Medical Intl Tech is −333% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Medical Intl Tech (MDLH)?
Revenue at Medical Intl Tech is growing −63.9% versus a year earlier (3y avg −18.2%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
Free · no account needed
Watch Medical Intl Tech in the live analysis
One click puts Medical Intl Tech on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Thin data
Sep 27, 2026